Immunovant Files 8-K for Regulatory Disclosure

Ticker: IMVT · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1764013

Sentiment: neutral

Topics: regulatory-filing, sec-disclosure

Related Tickers: IMVT

TL;DR

IMVT filed an 8-K, standard reporting, no major news.

AI Summary

Immunovant, Inc. filed an 8-K on January 14, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.

Why It Matters

This filing indicates Immunovant is meeting its regular reporting obligations with the SEC, providing transparency to investors about its financial status and any material disclosures.

Risk Assessment

Risk Level: low — This is a routine filing for regulatory compliance and does not appear to contain any new material information that would immediately impact the company's risk profile.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits as of January 14, 2025.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is January 14, 2025.

What is Immunovant, Inc.'s principal executive office address?

Immunovant, Inc.'s principal executive office address is 320 West 37th Street, New York, NY 10018.

What was Immunovant, Inc.'s former company name?

Immunovant, Inc.'s former company name was Health Sciences Acquisitions Corp.

Under which section of the Securities Exchange Act is this 8-K filed?

This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-01-14 08:09:34

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Immunovant, Inc. (the "Company") will provide a corporate overview for investors with a new corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. A copy of the presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Presentation, dated January 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOVANT, INC. By: /s/ Eva Renee Barnett Eva Renee Barnett Chief Financial Officer Date: January 14, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing